Medical device executives with designs on leveraging big data. Innovators pushing insurance companies to think differently. Leaders of startup accelerators ready to reveal what’s next.
Our speaker list continues to grow for MedCity CONVERGE, MedCityNews.com’s one-day event on healthcare innovation and convergence on July 10 in Philadelphia. Pfizer’s head of clinical innovation will talk about Big Pharma’s transition in a new era for medicine, the chief innovation officer of Children’s Hospital Boston will outline a vision of telemedicine, and a vice president from Medtronic will discuss how the digital health movement can best serve the medical device industry.
We’re two months away from the conference, but our early-bird ticket rate is ending this Friday. So if you want to see all the speakers below (and many more) for the best price possible you should buy your tickets now.
CONVERGE will put innovators of all stripes shoulder-to-shoulder with one another to talk about the next opportunities and the latest in cutting-edge solutions. In the coming weeks we’ll outline many of the startups contributing in the agenda, as well as those selected for our startup showcase – a largely hand-picked collection of early-stage companies showing how convergence is done.
There’s more to come. But here’s who is coming to participate in the CONVERGE agenda so far.
- Steve Auvil, partner, Benesch
- Andre Blackman, managing editor, Pulse & Signal
- Jessica Boden, president, Stone Arch Creative
- Jim Burns, CEO, AssureRx
- David Delaney, chief medical officer, SAP
- Ted Driscoll, technology partner, Claremont Creek Ventures
- Dr. Arlene A. Forastiere, senior vice president for medical affairs, eviti, and professor of oncology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
- Naomi Fried, chief innovation officer, Children’s Hospital Boston
- Kem Hawkins, CEO, Cook Medical
- Dr. Anil Jain, staff physician at Cleveland Clinic and senior vice president and chief medical information officer, Explorys
- Dr. Gary Kurtzman, vice president and managing director in life science group, Safeguard Scientifics
- Craig Lipset, head of clinical innovation, Pfizer
- Dr. Jennifer Lowry, Center for Personalized Medicine and Therapeutic Innovation, Children’s Mercy Hospital & Clinics
- Dr. Ken Riff, vice president of strategy and patient data management CRDM, Medtronic
- Don Rose, director of University of North Carolina’s Carolina KickStart Program
- Brandon Rowberry, vice president of innovation development, UnitedHealth Group
- Richard Russo, CEO, Endomedix
- Mike Scott, chairman, board of directors, National Organization for Rare Disorders
- Albert Shar, vice president, Robert Wood Johnson Foundation
- Steve Tang, president and CEO, University City Science Center of Philadelphia
- Brian Wells, associate chief information officer, Penn Medicine
- Dr. Brad Weinberg, founding partner, Blueprint Health
- David Williams, Health Business Blog
- Alan Ying, venture partner, Chrysalis Ventures
- Wil Yu, special assistant of innovations and research, Office of the National Coordinator for Health IT
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Remember, early-bird registration ends Friday, May 18. This is your last chance to save 40 percent off the ticket price. Don’t miss out on this opportunity to network, make deals, learn about where the industry is heading, see the coolest startups and connect with thought leaders and decision makers from across the healthcare ecosystem.
[Photo courtesy of Flickr user Caitlinator]
